In the run-up to the Heart Rhythm Society’s annual scientific sessions, Philips submitted its latest innovation in lead management for FDA clearance, advancing innovation in an increasingly important field.
Since their emergence over 60 years ago, implantable cardiac devices have made a significant positive impact for patients. Today, there are an estimated 13 million cardiac implanted electronic device leads worldwide, and another 1.4 million are implanted every year  . With more devices installed than ever and, as a result, more complications, the long-term management of patients is increasingly important. From infection, to vascular issues, to challenges with leads or the cardiac device itself, there are many reasons why both leads and devices may need to be removed and replaced during a patient’s lifetime. Philips’ lead management portfolio helps clinicians take the best course of action for each individual patient.
“As soon as a device is implanted, the patient’s anatomy starts to adapt. Over time, attachments form between the leads and the vessel walls, making their removal difficult and particular to each individual,” said Chris Duffie, Business Segment Leader for Lead Management at Philips. “Starting with the introduction of our laser system in 1997, we have led the way, continuously innovating in lead management and providing physicians with tools that are designed with safety in mind.”
Philips’ laser sheaths incorporate optical fibers arranged in a circle. The energy emitted from the tip ablates the tissue holding the lead, thereby freeing the lead in a controlled fashion. Philips offers the only laser sheath indicated for use in lead extraction procedures.